Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

SmithOnStocks Opines on Stocks May 19, Edition

One Approach for Investing in Emerging Biotechnology Stocks
I write on biotechnology and pharmaceutical companies of all sizes, but I have…
Read more…

Transcept: Throwing in the Towel on Intermezzo (TSPT, $3.56)

Intermezzo was launched by Transceptís marketing partner Purdue in April 2012. I believed then and now that it is a…
Read more…

Transcept: Throwing in the Towel on Intermezzo (TSPT, $3.59)

Intermezzo was launched by Transceptís marketing partner Purdue in April 2012. I believed then and now that it is a…
Read more…

Transcept: The Prescription Trend Watch for Intermezzo is On (TSPT, $6.63)

Introduction
Over the last year, I have written seven articles on Transcept (TSPT) and if you would like to have a…
Read more…

Transcept: Purdue Fires Big Marketing Guns and FDA Issues Insomnia Drug Guidelines That Help Intermezzo (TSPT, $5.72)

Investment Opinion
The launch of Intermezzo has been disappointing to investors thus far. Now, Transcept's (TSPT) marketing partner, Purdue Pharmaceuticals, is…
Read more…

Transcept: Direct to Consumer Advertising Campaign Could be the Tipping Point for Intermezzo

Investment Overview

The launch of Intermezzo began on April 4, 2012 and so far, it has been disappointing for investors. Purdue…
Read more…

The Launch of Transcept's Intermezzo by Purdue Has Begun (TSPT, $10.92)

Investment Opinion and Overview
Now is the moment of truth for Transcept (TSPT) as the launch of Intermezzo has begun. I…
Read more…

Investors' Concerns About the Intermezzo Launch Weighs on the Stock and Creates a Buying Opportunity

Investment View

I believe that Transceptís (TSPT) Intermezzo is an important new drug for insomnia and will be a commercial success.…
Read more…

Investors' Concern About Launch of Intermezzo Weighs on the Stock and Creates a Buying Opportunity (TSPT, $8.21)

Investment View
I believe that Transceptís (TSPT) Intermezzo is an important new drug for insomnia and will be a commercial success.…
Read more…

Transcept to Resubmit Intermezzo NDA; Hopes for a Class I Review

Resubmission of Intermezzo NDA

Transcept Pharmaceuticals in a press release today (September 15) said that it plans to resubmit its NDA…
Read more…

Transcept to Resubmit Intermezzo NDA; Hopes for a Class I Review (TSPT, $6.63)

Resubmission of Intermezzo NDA
Transcept Pharmaceuticals in a press release today (September 15) said that it plans to resubmit its NDA…
Read more…

Transcept Investment Thesis

Transcept just released a press release on July 12, 2011 with disappointing news on Intermezzo. The release reads as follows:

ďTranscept…
Read more…

Intermezzo is Likely to be Approved on its July 14, 2011 PDUFA Date; Then What (TSPT, $7.98)

Investment Thesis
Transceptís new drug for insomnia, Intermezzo, received a Complete Response Letter on October 26, 2009 in which the FDA…
Read more…

Transcept Releases Results of Highway Driving Study for Intermezzo and Plans to Re-Submit NDA in the First Quarter of 2011 (TSPT, $6.61)

Transcept believes that the results of the highway driving study of Intermezzo reasonably answer the concerns of the FDA that…
Read more…